Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status (1 selected)

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 38 of 38 results for ulcerative colitis

  1. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (DG22)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease

  2. Diverticular disease: diagnosis and management (NG147)

    This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.

  3. OSNA for colon cancer staging (MIB77)

    NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging

  4. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

  5. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (DG56)

    Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care

  6. Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

  7. Intrapartum care (NG235)

    This guideline covers the care of women and their babies during labour and immediately after birth. It focuses on women who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.

  8. Smartinhaler for asthma (MIB90)

    NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .